EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Mesenchymal stromal cell–derived extracellular vesicles in regenerative medicine: Standardisation, bioengineering and clinical translation

Yusuke Shimizu, Yoshikazu Inoue, Naoki Matsuura, Tatsuya Ishii, Yoshihiro Sowa, Hiroshi Sunami, Edward Hosea Ntege

Regenerative Therapy · 2026-03 · 31 · 101058

DOI: 10.1016/j.reth.2025.101058 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Regenerative Therapy, 2026-03. Verfasst von Yusuke Shimizu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Ja…. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) have emerged as promising cell-free therapeutics that recapitulate key paracrine functions of MSCs whilst mitigating limitations of viable-cell therapies. Clinical translation is hindered by inconsistent dose metrics, lack of validated potency assays, and manufacturing complexities. Here we review advances in MSC-EV standardisation, source and culture determinants, engineering and delivery platforms, and clinical applications, exemplified by chronic wound healing. We operationalise dual-metric dosing (particles plus protein) linked to mechanism-aligned potency assays, adopt a route-aware exposure-response framework to guide delivery strategies, and propose decision matrices aligning MSC sources and bioprocesses with indication-specific tasks. Good Laboratory Practice safety panels and Good Manufacturing Practice scale-up strategies are outlined to support regulatory readiness. Early clinical studies demonstrate feasibility and short-term safety but reveal heterogeneous efficacy, underscoring the need for harmonised dosing and potency measures. Collectively, these insights provide a roadmap to advance MSC-EVs as indication-matched regenerative medicines.

Schlagwörter

Stichwörter der Autor:innen

Bioengineering and biomaterialsClinical translationDose metrics and potency assaysGMP manufacturing and comparabilityMesenchymal stromal cell–derived extracellular vesiclesPharmacokinetics and biodistribution

Autor:innen und Institutionen

  • Department of Plastic and Reconstructive Surgery, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.
  • Department of Plastic and Reconstructive Surgery, School of Medicine, Fujita Health University, 1-98, Dengakugakubo, Kutsukake, Toyoake, Aichi, 470-1192, Japan.
  • Department of Plastic Surgery, School of Medicine, Jichi Medical University, 3311-1, Yakushiji, Shimotsuke-shi, Tochigi-ken, 329-049, Japan.
  • Center for Advanced Medical Research, Graduate School of Medicine, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa, 901-2725, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Shimizu, Y., Inoue, Y., Matsuura, N., Ishii, T., Sowa, Y., Sunami, H., & Ntege, E. H. (2026). Mesenchymal stromal cell–derived extracellular vesicles in regenerative medicine: Standardisation, bioengineering and clinical translation. Regenerative Therapy, 31, 101058. https://doi.org/10.1016/j.reth.2025.101058

Vancouver

Shimizu Y, Inoue Y, Matsuura N, Ishii T, Sowa Y, Sunami H, et al. Mesenchymal stromal cell–derived extracellular vesicles in regenerative medicine: Standardisation, bioengineering and clinical translation. Regenerative Therapy. 2026;31:101058. doi:10.1016/j.reth.2025.101058

BibTeX
@article{Shimizu2026,
  author = {Shimizu, Yusuke and Inoue, Yoshikazu and Matsuura, Naoki and Ishii, Tatsuya and Sowa, Yoshihiro and Sunami, Hiroshi and Ntege, Edward Hosea},
  title = {Mesenchymal stromal cell–derived extracellular vesicles in regenerative medicine: Standardisation, bioengineering and clinical translation},
  journal = {Regenerative Therapy},
  year = {2026},
  volume = {31},
  pages = {101058},
  doi = {10.1016/j.reth.2025.101058}
}
Kostenlos starten →